acut
myeloid
leukemia
aml
cancer
blood
bone
marrow
despit
advanc
chemotherapi
radiotherapi
firstlin
therapi
aml
result
longterm
diseasefre
surviv
patient
select
approach
target
cytotox
agent
cell
might
offer
promis
avenu
specif
elimin
residu
diseas
follow
classic
therapi
one
current
explor
experiment
approach
involv
viral
vectormedi
transduct
residu
acut
myeloid
leukem
cell
immunomodulatori
gene
describ
number
viral
vector
system
includ
lentivirus
retrovirus
adenovirus
adenoassoci
viru
amplicon
one
major
advantag
context
immunomodulatori
gene
transfer
preclin
observ
antileukem
bystand
effect
suggest
everi
cell
need
transduc
shown
instanc
tumor
necrosi
factora
granulocytemacrophag
colonystimul
factor
addit
mani
viral
vector
may
immunostimulatori
properti
upon
infect
cancer
cell
may
lead
increas
antigen
present
stimul
anticanc
immun
respons
howev
specif
target
viral
vector
leukem
cell
remain
signific
obstacl
addit
circul
virusspecif
antibodi
normal
act
neutral
viru
infect
therebi
like
counteract
viral
vectorbas
therapi
howev
addit
use
common
receptordepend
viru
entri
mechan
virus
certainusu
patholog
condit
also
use
antivir
antibodi
entri
target
cell
mechan
known
fcreceptormedi
antibodydepend
enhanc
viral
infect
propos
halstead
porterfield
colleagu
review
see
takada
kawaoka
concept
virusantibodi
complex
bind
cell
express
fc
receptor
cell
immun
system
includ
macrophag
monocyt
bcell
neutrophil
granulocyt
interact
fc
portion
antibodi
fc
receptor
cell
surfac
provid
bridg
mediat
attach
virus
cell
sever
human
fc
receptor
exist
exhibit
differ
immunoglobulin
ig
fc
tail
specif
high
affin
receptor
fcgri
effici
bind
human
addit
crossreact
mous
fcgri
highli
express
aml
cell
type
morpholog
accord
frenchamericanbritish
classif
system
absent
pluripot
stem
cell
hematopoiet
progenitor
cell
thu
fcgri
may
repres
appropri
aml
target
receptor
cytotox
agent
consid
normal
fcgriposit
immun
effector
cell
repopul
termin
fcgritarget
therapi
shown
recent
coronavirus
specif
retarget
select
cell
use
variou
type
bispecif
adapt
includ
singlechain
antibodi
prompt
us
explor
use
normal
virusspecif
antibodi
adapt
target
viral
vector
fcgri
molecul
express
cell
certain
type
aml
model
vector
use
mous
hepat
coronaviru
mhv
encod
firefli
luciferas
mhveflm
viru
normal
infect
murin
cell
specif
interact
spike
protein
cellular
receptor
murin
first
check
whether
viru
could
establish
infect
human
cell
via
fcgri
use
chimer
protein
compos
sbind
ndomain
fuse
human
fc
tail
nceacamfc
inocul
cell
human
aml
cell
lack
express
express
high
amount
fcgri
mhveflm
differ
multipl
infect
moi
absenc
presenc
differ
concentr
nceacamfc
protein
h
cell
lyse
luciferas
activ
measur
figur
show
nceacamfc
abl
mediat
infect
otherwis
refractori
cell
manner
depend
dose
viru
presenc
concentr
adapt
higher
concentr
nceacamfc
becom
increasingli
viru
neutral
next
analyz
number
antimhv
monoclon
antibodi
mab
abil
redirect
mhveflm
infect
fcgriposit
cell
use
set
avail
antibodi
known
mhv
protein
specif
igg
subclass
figur
serial
dilut
differ
mab
mix
mhveflm
inocul
onto
cell
h
inocul
luciferas
express
measur
interestingli
antibodi
test
mab
abl
effici
target
mhveflm
cell
none
other
effect
figur
nceacamfc
fusion
protein
contain
human
fc
tail
mab
mous
origin
fc
tail
describ
bind
human
fcgri
confirm
bind
receptor
analyz
whether
target
infect
mediat
nceacamfc
mab
could
block
preincub
cell
mab
antibodi
direct
thu
cell
treat
combin
result
demonstr
antibodi
direct
viral
vector
case
mhveflm
specif
fcgri
human
leukem
cell
effici
target
obvious
depend
specif
featur
antibodi
particularli
igsubclass
human
murin
effici
depend
viral
epitop
recogn
particular
antibodi
unclear
specif
given
viru
import
illustr
nice
antimhv
mab
subclass
recogn
differ
epitop
part
mhv
protein
latter
effect
fcgrimedi
mhv
infect
figur
antibodymedi
target
mhv
cell
featur
mab
use
viral
protein
specif
murin
igg
subclass
mhveflm
neutral
capac
determin
murin
cell
decreas
luciferas
express
rel
inocul
absenc
antibodi
mhvm
refer
viral
membran
protein
part
spike
protein
respect
b
mhveflm
tcid
unit
inocul
onto
human
cell
presenc
differ
antimhv
mab
variou
dilut
h
inocul
luciferas
lysi
buffer
ad
cell
suspens
total
luciferas
express
measur
data
repres
experi
besid
coronavirus
variou
virus
describ
use
fc
receptor
altern
entri
pathway
exampl
includ
hiv
polioviru
yellow
fever
viru
influenza
viru
therefor
use
antibodi
target
viral
vector
aml
cell
may
also
applic
viral
vector
system
clearli
everi
mab
abl
target
particular
viru
fcgri
howev
sever
virus
specif
fc
receptor
target
antibodi
alreadi
identifi
compar
viral
vector
target
strategi
use
igg
antibodi
may
offer
easi
oftheshelf
target
potenti
system
deliveri
viral
vector
therefor
studi
antibodymedi
target
viral
vector
fc
receptor
express
cell
certain
type
aml
warrant
one
hotspot
chromosom
alter
includ
duplic
transloc
frequent
detect
hematolog
malign
consequ
aberr
gene
may
becom
deregul
fusion
gene
may
form
interfer
normal
program
cell
growth
differenti
report
patient
occur
acut
myeloid
leukemia
aml
anteced
myelodysplast
syndrom
md
patient
male
case
sihmd
seri
diagnos
progress
md
hematolog
data
follow
red
blood
cell
l
hemoglobin
gl
white
blood
cell
l
platelet
count
l
bone
marrow
bm
biopsi
marrow
hypercellular
ratio
normal
myeloblast
promyelocyt
increas
consist
myelodysplast
syndrom
progress
acut
myeloid
leukemia
patient
treat
cyclophosphamid
vincristin
cytosin
arabinosid
prednison
coap
combin
therapi
cytogenet
analysi
rband
techniqu
unstimul
bm
cell
admiss
reveal
chromosom
transloc
metaphas
among
analyz
figur
chromosom
transloc
also
confirm
chromosom
paint
cp
use
whole
cp
probe
chromosom
visual
fcgrimedi
mhv
infect
cell
amount
tcid
unit
mix
nceacamfc
mab
inocul
onto
cell
h
infect
cell
immunofluoresc
stain
use
mhvspecif
antibodi
